Toggle light / dark theme

Supporting the concept that GLP1 agonist drugs lower BloodPressure independent from their weight loss effects

Daniel J. Drucker & team identify the vascular smooth muscle GLP-1 receptor as a key cellular target for the actions of GLP-1 medicines to lower blood pressure.

The figure: Renal GLP1R/Glp1r is expressed in human and murine vascular smooth muscle cells (VSMCs) and Glp1rVSM-/- mice have reduced Glp1r transcripts in renal tissues.


1Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.

2Section of Nephrology, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.

Address correspondence to: Daniel J. Drucker, Mt. Sinai Hospital, 600 University Ave. Mailbox 39, Toronto, Ontario, Canada, M5G1X5. Phone: 416.361.2661; Email: [email protected].

Leave a Comment

Lifeboat Foundation respects your privacy! Your email address will not be published.

/* */